PL2201012T3 - Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b - Google Patents

Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b

Info

Publication number
PL2201012T3
PL2201012T3 PL08806741T PL08806741T PL2201012T3 PL 2201012 T3 PL2201012 T3 PL 2201012T3 PL 08806741 T PL08806741 T PL 08806741T PL 08806741 T PL08806741 T PL 08806741T PL 2201012 T3 PL2201012 T3 PL 2201012T3
Authority
PL
Poland
Prior art keywords
pyrrolo
inhibitors
protein kinase
pyrimidin derivatives
pyrimidin
Prior art date
Application number
PL08806741T
Other languages
English (en)
Inventor
Paul David Johnson
Andrew Leach
Richard William Arthur Luke
Zbigniew Stanley Matusiak
Jeffrey James Morris
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2201012(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2201012T3 publication Critical patent/PL2201012T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08806741T 2007-10-11 2008-10-09 Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b PL2201012T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97919207P 2007-10-11 2007-10-11
US4786208P 2008-04-25 2008-04-25
EP08806741.8A EP2201012B1 (en) 2007-10-11 2008-10-09 Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
PCT/GB2008/050925 WO2009047563A1 (en) 2007-10-11 2008-10-09 Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors

Publications (1)

Publication Number Publication Date
PL2201012T3 true PL2201012T3 (pl) 2014-11-28

Family

ID=40251789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08806741T PL2201012T3 (pl) 2007-10-11 2008-10-09 Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b

Country Status (43)

Country Link
US (8) US8101623B2 (pl)
EP (1) EP2201012B1 (pl)
JP (2) JP4705695B2 (pl)
KR (1) KR101494734B1 (pl)
CN (1) CN101861321B (pl)
AR (1) AR068846A1 (pl)
AU (1) AU2008309383B2 (pl)
BR (1) BRPI0818533B8 (pl)
CA (1) CA2701057C (pl)
CL (1) CL2008003023A1 (pl)
CO (1) CO6270328A2 (pl)
CR (1) CR11359A (pl)
CU (1) CU23886B1 (pl)
CY (1) CY1116929T1 (pl)
DK (1) DK2201012T3 (pl)
DO (1) DOP2010000103A (pl)
EA (1) EA018512B1 (pl)
ES (1) ES2522365T3 (pl)
FI (1) FIC20240039I1 (pl)
FR (1) FR24C1046I2 (pl)
GT (1) GT201000082A (pl)
HN (1) HN2010000653A (pl)
HR (1) HRP20140807T1 (pl)
HU (1) HUS2400038I1 (pl)
IL (1) IL204721A (pl)
LT (1) LTC2201012I2 (pl)
ME (1) ME01999B (pl)
MX (1) MX2010003927A (pl)
MY (1) MY150059A (pl)
NI (1) NI201000050A (pl)
NL (1) NL301299I2 (pl)
NO (1) NO2024050I1 (pl)
NZ (1) NZ585261A (pl)
PE (2) PE20090964A1 (pl)
PL (1) PL2201012T3 (pl)
PT (1) PT2201012E (pl)
RS (1) RS53552B1 (pl)
SA (1) SA08290625B1 (pl)
SI (1) SI2201012T1 (pl)
TW (1) TWI453021B (pl)
UY (1) UY31384A1 (pl)
WO (1) WO2009047563A1 (pl)
ZA (1) ZA201002318B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
EP2057187B1 (en) * 2006-08-10 2016-12-28 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
WO2011002772A1 (en) * 2009-06-29 2011-01-06 Oncotherapy Science, Inc. Imidazopyridine derivatives and pbk inhibitors containing the same
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
AU2012205601B2 (en) 2011-01-11 2016-03-24 Novartis Ag Combination
MY169449A (en) * 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
JP6295578B2 (ja) * 2013-09-30 2018-03-20 凸版印刷株式会社 反応容器、核酸解析装置、および核酸解析方法
EP3718544A1 (en) * 2013-10-01 2020-10-07 Novartis AG Combination
RS59559B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP6538725B2 (ja) * 2014-05-28 2019-07-03 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ａｚｄ５３６３の製造方法およびそれに用いられる新規中間体
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
HUE070538T2 (hu) * 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
BR112022003490A2 (pt) 2019-08-26 2022-05-24 Arvinas Operations Inc Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
FI4054582T3 (fi) 2019-11-04 2025-12-04 Astrazeneca Ab Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon
MX2022011188A (es) * 2020-03-17 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
EP4271678A1 (en) * 2021-01-04 2023-11-08 Teva Pharmaceuticals International GmbH Solid state forms of capivasertib and process for preparation thereof
CN116925080B (zh) * 2022-03-29 2025-12-12 杭州健崃生物科技有限公司 作为Akt蛋白激酶抑制剂的化合物及其制备方法和用途
US20250205233A1 (en) 2022-03-31 2025-06-26 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CN114601836B (zh) * 2022-04-12 2022-12-06 四川大学华西医院 一种akt抑制剂在制备治疗乳腺癌的药物中的应用
KR20250089532A (ko) 2022-10-17 2025-06-18 아스트라제네카 아베 암 치료를 위한 serd의 조합
JP2025539034A (ja) 2022-11-11 2025-12-03 アストラゼネカ・アクチエボラーグ 癌の治療のための併用療法
CN120202006A (zh) 2022-11-15 2025-06-24 阿斯利康(瑞典)有限公司 卡帕塞替尼和维奈托克的治疗组合
CN121175036A (zh) 2023-05-26 2025-12-19 阿斯利康(瑞典)有限公司 药物组合物
CN121218987A (zh) 2023-06-02 2025-12-26 阿尔维纳斯运营股份有限公司 雌激素受体降解剂和akt抑制剂的组合
WO2025176877A1 (en) 2024-02-22 2025-08-28 Astrazeneca Ab Therapeutic combination of an akt inhibitor, a bcl-2 inhibitor, and an anti-cd20 antibody
WO2025238662A1 (en) * 2024-05-15 2025-11-20 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide and its salts

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (pl) 1963-04-04 1900-01-01
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CN1125817C (zh) 1996-02-13 2003-10-29 曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20020192228A1 (en) 1997-02-12 2002-12-19 Samir M. Hanash Protein markers for lung cancer and use thereof
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EA200000098A1 (ru) 1997-08-05 2000-08-28 Пфайзер Продактс Инк. 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CO5280092A1 (es) 2000-02-15 2003-05-30 Sugen Inc Indolinas susutituidas con pirroles inhibidoras de proteinquinasas
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU784297C (en) 2000-06-26 2007-01-11 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2420177C (en) 2000-08-31 2008-07-08 F. Hoffmann-La Roche Ag Quinazoline derivatives as alpha-1 adrenergic antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CN1263757C (zh) 2000-12-01 2006-07-12 Osi制药公司 特异于腺苷a1,a2a和a3受体的化合物及其应用
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
ATE327236T1 (de) 2002-01-07 2006-06-15 Eisai Co Ltd Desazapurine und deren verwendung
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
TW200410688A (en) * 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
US20060159617A1 (en) 2002-11-08 2006-07-20 Ashfaq Mahmood Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
BR0316991A (pt) * 2002-12-04 2005-10-25 Eisai Co Ltd Compostos de anel de 1,3-diidro-imidazol fundido
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
JP2006519846A (ja) 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
US20060128956A1 (en) 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
WO2005063704A1 (ja) * 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. アゼチジン環化合物およびその医薬
US7470701B2 (en) * 2004-03-30 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Substituted 2,5-heterocyclic derivatives
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
EP2029592A1 (en) 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑

Also Published As

Publication number Publication date
EA201000552A1 (ru) 2010-12-30
WO2009047563A1 (en) 2009-04-16
CL2008003023A1 (es) 2009-11-27
KR101494734B1 (ko) 2015-02-26
HK1143154A1 (en) 2010-12-24
HRP20140807T1 (hr) 2014-11-21
ZA201002318B (en) 2012-09-26
ES2522365T3 (es) 2014-11-14
US20200239483A1 (en) 2020-07-30
JP5330430B2 (ja) 2013-10-30
FR24C1046I1 (fr) 2025-01-10
CU20100062A7 (es) 2011-10-05
US20240109902A1 (en) 2024-04-04
KR20100101077A (ko) 2010-09-16
CO6270328A2 (es) 2011-04-20
US20090163524A1 (en) 2009-06-25
UY31384A1 (es) 2009-05-29
CY1116929T1 (el) 2017-04-05
US11236095B2 (en) 2022-02-01
US11760760B2 (en) 2023-09-19
EP2201012A1 (en) 2010-06-30
SA08290625B1 (ar) 2012-02-12
SI2201012T1 (sl) 2014-10-30
US10654855B2 (en) 2020-05-19
CN101861321A (zh) 2010-10-13
JP2011157364A (ja) 2011-08-18
US20170057969A1 (en) 2017-03-02
US20180312516A1 (en) 2018-11-01
HUS2400038I1 (hu) 2024-12-28
MX2010003927A (es) 2010-04-30
AU2008309383A1 (en) 2009-04-16
LTPA2024532I1 (pl) 2024-12-10
FR24C1046I2 (fr) 2025-10-10
NZ585261A (en) 2011-10-28
AR068846A1 (es) 2009-12-09
TW200927128A (en) 2009-07-01
US20120190679A1 (en) 2012-07-26
CR11359A (es) 2010-07-15
CA2701057A1 (en) 2009-04-16
BRPI0818533A2 (pt) 2017-06-06
NO2024050I1 (no) 2024-11-18
US20220220116A1 (en) 2022-07-14
PT2201012E (pt) 2014-09-04
US8101623B2 (en) 2012-01-24
IL204721A (en) 2013-10-31
GT201000082A (es) 2015-03-10
BRPI0818533B8 (pt) 2021-05-25
NL301299I2 (nl) 2024-12-11
EA018512B1 (ru) 2013-08-30
JP4705695B2 (ja) 2011-06-22
HN2010000653A (es) 2013-03-18
EP2201012B1 (en) 2014-06-25
TWI453021B (zh) 2014-09-21
CA2701057C (en) 2015-03-24
IL204721A0 (en) 2010-11-30
US9492453B2 (en) 2016-11-15
US20150182531A1 (en) 2015-07-02
ME01999B (me) 2015-05-20
CN101861321B (zh) 2013-02-06
US12252495B2 (en) 2025-03-18
DOP2010000103A (es) 2010-05-31
LTC2201012I2 (pl) 2025-12-10
RS53552B1 (sr) 2015-02-27
CU23886B1 (es) 2013-04-19
PE20130152A1 (es) 2013-03-17
JP2011500547A (ja) 2011-01-06
NI201000050A (es) 2011-12-22
PE20090964A1 (es) 2009-08-15
DK2201012T3 (da) 2014-09-08
US10059714B2 (en) 2018-08-28
BRPI0818533B1 (pt) 2020-12-01
FIC20240039I1 (fi) 2024-11-12
AU2008309383B2 (en) 2012-04-19
MY150059A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
SI1893612T1 (sl) Pirolo b piridin derivati kot protein kinazni inhibitorji
HUE041382T2 (hu) Pirrolo[2,3-d]pirimidin származékok janus-kináz inhibitorként
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
ZA201101701B (en) Pyrrolo[2,3-d]pyrimidine compounds
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
IL207224A0 (en) Pyrrolo [2,3-d] pyrimidines and use thereof as tyrosine kinase inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IL217798A0 (en) Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
ZA200803173B (en) Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors
HK1112231A (en) Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors
HK1160846A (en) [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors